Pörssitiedote

Lumito and Offspring Biosciences initiate pilot study to combine automated, standardised workflows with high‑sensitivity tissue analysis

Lumito AB (publ) (“Lumito” or the “Company”) and Offspring Biosciences Sweden AB (“Offspring Biosciences”) today announce the initiation of a pilot study. The purpose is to evaluate the integration of Lumito’s proprietary tissue labelling and high-sensitivity imaging platform within Offspring Biosciences’ automated analytical workflows based on Roche Ventana Discovery Ultra. The pilot study will commence in April 2026.

A key objective of the pilot study is to assess and ensure compatibility between Lumito’s SCIZYS platform and Roche Ventana’s Discovery Ultra. With compatibility already established with the Leica Bond RX system, as communicated by Lumito on 13 August 2025, successful testing with Roche Ventana will allow access to the two largest platforms in automated and digital pathology.

The two parties see strong potential in pairing Offspring Biosciences’ highly standardised, automated staining workflows with the exceptionally high sensitivity and quantitative capabilities of Lumito’s SCIZYS platform. The combination of controlled, reproducible sample preparation together with autofluorescence free digital imaging offers a unique opportunity to deliver highly consistent, quantitative, and sensitive tissue analysis in pharmaceutical and biotechnology applications.

“We are excited and very pleased to conduct this pilot study with Offspring Biosciences, a CRO well known for its vast experience and expertise in pathology and tissue analysis. Ensuring performance with the automated staining systems from Roche Ventana is an important step toward scalable adoption. Automation is central to modern pathology and drug development workflows, and we are committed to enabling smooth integration into standardised laboratory processes”, says Sanna Wallenborg, CEO of Lumito.

Offspring Biosciences provides advanced cell- and tissue-based analytical services to pharmaceutical and biotechnology companies, supporting target validation, antibody characterisation, and translational research directly in human tissue.

“Our mission as a strategic translational partner is to help biopharma clients bridge the translational gap by delivering decision-critical, human-tissue-based data,” says Åsa Johansson, CEO of Offspring Biosciences. By evaluating Lumito’s high-sensitivity UCNP technology on our automated Ventana platforms, we aim to push the boundaries of signal-to-noise ratios and target quantification. This pilot aligns perfectly with our commitment to providing the pharma-grade 'Deep Insights' required to confidently de-risk Phase II clinical development.”

The collaboration entails no financial or commercial obligations for either party beyond the execution of the pilot study.

About Offspring Biosciences
Offspring Biosciences is a highly specialized, tissue-first translational partner for the global pharma and biotech industry. The company combines the scientific depth of a major pharma R&D unit with the speed, agility, and elite focus of a specialized translational team. Offspring bridges the industry's "Translational Gap" by validating drug targets and antibody performance directly in human disease tissues. Leveraging advanced molecular pathology techniques – such as multiplex IHC, ISH, and isPLA –together with AI-assisted digital pathology, Offspring transforms subjective imagery into quantitative, statistically robust data ("Pixels to P-Values"). By aligning its services with the "5R" drug development framework, Offspring provides the deep insights needed to proactively reduce late‑stage attrition and de‑risk clinical development. www.offspringbiosciences.se

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.